Clinical Management Guideline for Acute Myeloid Leukaemia
|
|
- Shona Hopkins
- 5 years ago
- Views:
Transcription
1 Clinical Management Guideline for Acute Myeloid Leukaemia Document Control Prepared by: Mark Drummond, Anne Parker, John Murphy Approved by: RCAG Prescribing Advisory Subgroup Issue date: December 2009 Review date: December 2011 Version: Version 1.0
2 Contents 1. Initial Presentation Initial Management... 4 If APL suspected... 4 All AML patients Patients < 60yrs (or selected fit pts > 60yrs)... 4 Prognostic Information (<60yrs)... 6 a) Cytogenetically / molecularly determined risk group:...6 b) Conventional MRC approach (from MRC AML 10 & 12 trial data):.. 6 c) AML 17 Risk Score:... 7 Further Management during intensive therapy... 7 Choice of Intensive Therapy... 8 Assessment of Response... 8 Definitions of Response... 8 Indications for Consideration of Allogeneic SCT in 1 st CR:... 9 Management of Refractory / Relapsed Disease Outwith Study... 9 a) Refractory Disease... 9 b) Management of Relapse Patients > 60yrs or Frail a) Intensive Therapy b) Non-Intensive Therapy Follow Up Following Completion of Therapy Supportive Care References & Additional Reading (Hyperlinked) Summary Flow Chart CMG for Acute Myeloid Leukaemia Page 2 of 12
3 1. Initial Presentation 1. History to include symptoms of infection, bleeding +/- bruising, occupation, previous chemotherapy/ radiotherapy exposure, neurological symptoms, comorbidities & siblings. 2. Examination include fundi, skin & gums for infiltration 3. Assess performance status 4. Measure height & weight 5. If patient is aged < 26 years discuss at Regional MDT & consider transfer to Teenage Cancer Unit at BOC and discussion with teenage cancer team including Clic Sergeant SW and Clinical Nurse Specialist (contact via switchboard or direct ). 6. Laboratory Tests a. FBC manual differential & film b. Coagulation screen Fibrinogen, D dimers c. U+E d. LFT e. Urate f. LDH g. G+S h. ECG i. CMV serostatus if potential HSCT allograft candidate (generally <60yrs or >60yrs in AML16 trial Intensive Pathway). j. Tissue typing if potential HSCT allograft candidate. k. Check HIV, Hep B, Hep C status. l. Consent for Research Blood Sample (50mls if peripheral blasts) using Generic Consent form. Tel to inform research team (Paul O Gorman) and keep in 4 0 C overnight if required. m. Infection screen if clinically infected including blood cultures, MSU, stool sample n. Bone marrow aspirate. o. Bone marrow trephine- only if dry tap or no particles in aspirate. Carry out trephine roll in this situation, put part of sample into cytogenetics medium and agitate, plus part of sample into formalin. p. Cytogenetics preferably on bone marrow but PB can be used. If no aspirate available and no/ low circulating blasts send trephine sample in media. q. Immunophenotyping (including sample to GGH for central markers to establish baseline leukaemia-associated phenotype / MRD marker in case of subsequent transplant). r. Molecular biology sample (bone marrow). NB cytogenetics fails to detect 15% of patients who would fall into the good risk group. s. LP if neurological symptoms and imaging normal flow cytometry, cytospin, MC+S, glucose, protein. Needs to get to flow lab within 4 hours. 7. Imaging a. CXR b. CT/ MR scan if neurological symptoms 8. Discuss patient at MDT (Local or Regional) CMG for Acute Myeloid Leukaemia Page 3 of 12
4 2. Initial Management If APL suspected 1. Correct coagulation aggressively maintain fibrinogen >1.0g/dl with cryoprecipitate, and plts > 50 x10 9 /l, normalise PT & PTT with FFP. This should happen even if not clinically haemorrhagic. 2. Start ATRA 45mg/m 2 immediately (including presentations out of hours) if suspicious of diagnosis & monitor for ATRA syndrome. 3. If WCC >10 Idarubicin doses should be brought forward by one day in patients presenting with WBC>10, with first dose given within a few hours of starting ATRA. Consider giving prophylactic dexamethasone 10mg IV 12- hourly, although evidence lacking for this prophylactic approach. 4. If ATRA syndrome suspected clinically (unexplained fever, weight gain, respiratory distress, pulmonary infiltrates, pleural or pericardial effusion) start dexamethasone 10mg i.v. 12 hourly (to continue for a minimum of 3 days and until disappearance of symptoms & signs). ATRA should be temporarily interrupted only in severe cases. 5. Arrange urgent cytogenetics: telephone to alert lab to urgent sample. If sample is received before 12pm FISH can be performed on the same day. All AML patients 1. Treat any infection according to local antibiotic policy for the immunocompromised 2. Start allopurinol, acyclovir 400mg bd, azole prophylaxis (withhold if myelotarg being considered), ciprofloxacin 500mg bd if does not require iv antibiotics 3. Correct coagulation abnormalities MUST be done aggressively if APL suspected (see above) 4. Monitor K+ levels 5. Rehydrate as required, maintain good diuresis with iv fluids if necessary 6. Assess re requirement for leucopheresis confusion, retinal changes, headache. Do NOT leucopherese if APL suspected 7. Correct Hb if clinically indicated UNLESS signs of leucostasis. If WCC high eg >100 do not transfuse unless patient is symptomatic and then only slowly. Use CMV neg products until CMV status known in HSCT potential candidates 8. Discuss any clinical trials available eg AML 17, AML 16 and conventional chemotherapy. Allow patient time to read PIS. 9. Consent for agreed therapy 10. It is important to commence definitive chemotherapy promptly in young patients (<60yrs) as outcomes are better if treatment is started within 5 days of diagnosis Patients < 60yrs (or selected fit pts > 60yrs) 11. Assess re risk of tumour lysis syndrome if LDH >2xULN, WCC >50, Urate >0.5 consider rasburicase (particularly if monoblastic). Daily U+E, Ca 2+, PO 4, urate until WCC <10. NB if already receiving rasburicase urate will be falsely low. 12. Echo if previous history of cardiac problems or previous chemotherapy CMG for Acute Myeloid Leukaemia Page 4 of 12
5 13. Fertility counselling re loss of fertility for premenopausal women and men, counselling re risk of partners pregnancy for men whilst on chemotherapy. Discuss sperm storage if deemed appropriate. 14. Tissue typing sample + VUD form if potential allograft candidate a. This includes patients >60 entering AML16 intensive arm a. Details of siblings to Clinical Apheresis Unit CMG for Acute Myeloid Leukaemia Page 5 of 12
6 Prognostic Information (<60yrs) This can be determined in 3 different ways: a) Cytogenetically / molecularly determined risk group: Risk Group Karyotype marker* Molecular marker Good risk Intermediate risk Poor risk t(15;17) t(8;21) inv(16) t(16;16) Normal cytogenetics Abnormalities NOT included in good or poor risk groups >2 abnormalities t(9;22) q- 7q- 11q23 except for t(9;11) t(6;9) inv(3) PML/RARA AML1/ETO CBFB/MYH11 Normal cytogenetics with NPM1 or CEBPA (& Flt-3 negative). All these patients require molecular analysis (Flt-3, NPM1, CEBPA). Normal cytogenetics with Flt3 ITD *In the event of a failed marrow aspirate it is vital that either a trephine or PB sample (if adequate circulating blasts) is sent to cytogenetics lab. If metaphase preps fail it is necessary to get as full a FISH & molecular profile as possible. Suggest discuss directly with relevant lab in light of morphological / clinical features to guide testing. NB molecular markers for t(8;21) and inv(16) are NOT done as part of AML17 b) Conventional MRC approach (from MRC AML 10 & 12 trial data): Good risk: Any patient with favourable genetic abnormalities t(8;21), inv(16), t(15;17),irrespective of other genetic abnormalities or marrow status after Course 1. Standard: Any patient not in either good or poor risk groups. Poor risk: Any patient with more than 15% blasts* in the bone marrow after Course 1, or with adverse genetic abnormalities: -5, -7, del(5q), abn (3q) or complex (5 or more abnormalities) and without favourable genetic abnormalities. Risk Group 5 Year Survival 5 Year Relapse rate Good 76% 25% Standard 48% 52% Poor 21% 73% CMG for Acute Myeloid Leukaemia Page 6 of 12
7 NB: *In AML12, patients with >15% blasts after cycle 1 have a poor outlook (5 year survival of 26%), while partial remitters (5-15% blasts) do only slightly worse than complete remitters (5 year survivals of 44% and 56% respectively). c) AML 17 Risk Score: See associated Excel file for calculation. Developed from AML12 data, tested prospectively on AML 15 cohort as below: Pending further clarification from trial data it is reasonable to manage patients as per risk group determined by any or all of the above methods. Further Management during intensive therapy 1. In APL or cases with propensity for fibrinolysis / DIC (eg monocytic lineage) twice daily coagulation screen to include fibrinogen and D Dimers until WCC<1.0 or coagulation returned to normal whichever is achieved last. 2. In patients with monocytic lineage leukaemia and high WCC ie. >50 consider giving Dexamethasone 8mg daily to reduce risk of pneumonitis. 3. Regular FBC, U&E, LFT to assess requirement for blood products (see local policies), renal function and drug toxicity 4. If the patient develops a pyrexia >38 0 C they should be treated according to local policies for neutropenic sepsis 5. Irradiated blood products are ONLY required for patients who have been given CLOFARABINE or FLUDARABINE 6. CMV negative blood products are ONLY required if CMV neg AND candidate for HSCT (note that all CMV negative blood products are now irradiated) 7. G-CSF should not be used routinely, but may be commenced in patients who are slow to recover or have significant infections. NB this may make BM interpretation at the time of count recovery more difficult CMG for Acute Myeloid Leukaemia Page 7 of 12
8 Choice of Intensive Therapy See flow chart for treatment summary. Ideally pts suitable for intensive therapy should be entered into the age appropriate clinical trial (for those >60yrs see below). The standard approach outwith study is DA 3+10 followed by DA 3+8 (i.e. 2 induction cycles) followed by two cycles of HD ARA-C (1.5g/m 2 ). The latter appears to be at least as effective as the conventional MACE / MiDAC approach (AML 15 data, unpublished) and is more straightforward (although the latter regimes are an acceptable alternative). Assessment of Response 1. This should be done once the patient has neutrophil count> 0.5 x 10 9 /l 21 days from the end of chemotherapy without count recovery. If a hypoplastic BM this should be repeated every 7-10 days until recovers circulating blasts are identified in the peripheral blood 2. This should be done by Bone marrow aspirate morphology (trephine is NOT required unless dry tap) Cytogenetics ONLY if previously abnormal Molecular studies ONLY if previously abnormal Immunophenotyping (FU sample to GGH if sent at diagnosis) 3. This only requires to be repeated after subsequent courses if they are more than 28 days from the end of chemotherapy without count recovery circulating blasts are identified in the peripheral blood Cytogenetics ONLY if abnormal after previous course Molecular studies have MRD marker Immunophenotyping ONLY if MRD marker 4. After completion of cycle 1 assign risk group as detailed above. Definitions of Response 1. Complete Remission (CR): The bone marrow is regenerating normal haemopoietic cells and contains <5% blast cells by morphology in an aspirate sample with at least 200 nucleated cells. Additionally there is an absolute neutrophil count of more than 1.0 x 10 9 /l and platelet count of at least 100 x 10 9 /l. 2. Complete Remission with incomplete recovery (CRi): Fulfilling all criteria for CR except for residual neutropenia (<1.0 x 10 9 /l) or thrombocytopenia (<100 x 10 9 /l). 3. Partial Remission (PR): The bone marrow is regenerating normal haemopoietic cells and blast count has reduced by at least half, to a value between 5 and 25% leukaemic cells. 4. Resistant Disease (RD): The bone marrow shows persistent AML, and patient survives at least 7 days beyond end of course. CMG for Acute Myeloid Leukaemia Page 8 of 12
9 Indications for Consideration of Allogeneic SCT in 1 st CR outwith trial: Age >35 yrs & preceding MDS or Poor Risk Age < 35 yrs, either Standard or Poor Risk (not good risk patients) who are NPM1 negative. This is an evolving indication: please discuss individual patients with BMTU. Management of Refractory / Relapsed Disease Outwith Study a) Refractory Disease Patients who do not respond to induction therapy i.e. fail to have a blast count <15% should be considered for allosct. Prior remission induction should be attempted with alternative regimen such as FLAG-Ida. b) Management of Relapse Such patients should be discussed at relevant MDT and clinical trial considered if available. It is important to consider relevant prognostic factors before attempting salvage therapy in this setting (see below). Early relapses (< 6 months) do particularly poorly. 3 main factors are relevant: 1. Duration of first remission* 2. Patient age 3. Cytogenetics at the time of original presentation The decision to treat the patient with relapsed disease should take into account prognostic factors. The HOVON prognostic index 2 (see table and subgroups below) can be used to define outcome risk and should be used to aid decision making. Three prognostic sub-groups can be defined. Patients with prognostic scores of may be considered for palliation or experimental therapy. Group A: Overall survival 70% at 1 year and 46% at 5 years Score 1-6 Group B: Overall survival 49% at 1 year and 18% at 5 years Score 7-9 Group C Overall survival of 16% at 1 year and 4% at 5 years Score CMG for Acute Myeloid Leukaemia Page 9 of 12
10 HOVON Prognostic Factor Points Relapse-free interval from first complete remission, months >18 months months 3 6 months 5 Cytogenetics at diagnosis t(16;16) or inv(16)* 0 t(8;21)* 3 Other 5 Age at first relapse 35 years years 1 > 45 years 2 Stem-cell transplantation before first relapse No SCT 0 Previous SCT (allogeneic or autologous) 2 Although the optimal salvage regimen for patients with relapsed disease is unknown, most regimens rely upon high-dose cytarabine in combination with other chemotherapeutic agents e.g. FLAG or FLAG-Ida, or as single agent. Patients deemed suitable for intensive salvage therapy should be discussed with the Transplantation team. * In patients experiencing late relapse (> 2years from 1 st CR) consolidation with an autograft can be considered in place of allogeneic SCT. 4. Patients > 60yrs or Frail a) Intensive Therapy The decision to treat with intensive (curative) therapy or palliate is a key one and is made on an individual basis. In general pts over the age of 60 may be considered for intensive therapy if they have a good PS (ECOG 0-2): if a patient is clearly a candidate for intensive therapy it is reasonable to start induction treatment in the absence of cytogenetic data. Ideally treatment should be on a clinical trial (eg intensive arm of AML 16 or AML17); the optimal induction therapy for these patients remains unknown (DA 3+7 is standard). Local experience is that FLAG is well tolerated in this setting but there is no evidence that it is superior. 2-3 cycles of therapy are likely to be optimum. For poor risk pts consider RIC if remission is achieved. Management of such patients should largely be as described for < 60 yrs above. b) Non-Intensive Therapy This is appropriate for frail (ECOG > 2) or elderly patients. Where possible enter patients into AML 16 non-intensive arm. Standard treatment is LD ARA C, 20mg bd for 10 days. The CR rate is 18% with this therapy, although pts who have poor risk cytogenetics are unlikely to respond and may be considered for supportive care (+/- hydroxycarbamide) only (AML 14 results 3 ). It is therefore appropriate to delay definitive management while cytogenetics are awaited. CMG for Acute Myeloid Leukaemia Page 10 of 12
11 5. Follow Up After Completion of Therapy 1. Stop prophylactic medication unless previous fludarabine/ clofarabine. In this circumstance it seems reasonable to continue PCP prophylaxis for 6 months. 2. Regular FBC 3. Consider venesection programme after 4-6 months if Hb in normal range, and if pt treated with curative intent If ferritin >1000 and &/or Transferrin Saturation > 50%. Ferritin >1000 and deranged LFTs 4. Review 1 monthly for 6 months post therapy 2 monthly until 1 year post therapy 3-4 monthly until 3 years post therapy 6 monthly to 4 years and then consider annually Consider referral to late effects clinic (if available) from 4 years post therapy 6. Supportive Care As a minimum the following policies should be available to the clinical care team Blood product transfusion Antimicrobial prophylaxis and treatment Care of Neutropenic sepsis Tumour lysis Mouth care Long term indwelling catheter care 7. References & Additional Reading (Hyperlinked) Guidelines on management of AML (BCSH) Practical Guidelines for Oncology Acute myeloid leukaemia (NCCN) Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Sanz, M.A. et al (2009) Blood, 113, AML 17 website AML 16 website Guidelines on the management of invasive fungal infection during therapy for haematological malignancy (BCSH) Guidelines On The Insertion And Management Of Central Venous Access Devices In Adults (BCSH) Obtaining Consent for Chemotherapy (BCSH) 1. Sekeres MA, Elson P, Kalaycio ME, et al. Time from diagnosis to treatment initiation predicts survival in younger, but not older, acute myeloid leukemia patients. Blood. 2009;113: CMG for Acute Myeloid Leukaemia Page 11 of 12
12 2. Breems DA, Van Putten WLJ, Huijgens PC, et al. Prognostic Index for Adult Patients With Acute Myeloid Leukemia in First Relapse. J Clin Oncol. 2005;23: Alan KB, Donald M, Archie GP, et al. A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment. Cancer. 2007;109: Summary Flow Chart See over: CMG for Acute Myeloid Leukaemia Page 12 of 12
13
North West London Cancer Network
GUIDELINES FOR THE MANAGEMENT OF ADULT ACUTE LEUKAEMIA INITIAL MANAGEMENT CONSIDERATIONS N.B.: If AML is suspected definitively diagnosed, please ensure that the patient is transferred immediately f treatment
More informationTretinoin - ATRA (All Trans Retinoic Acid)
Tretinoin - ATRA (All Trans Retinoic Acid) Indication Treatment of acute promyelocytic leukaemia (APML) Used in combination with chemotherapy. ICD-10 codes C92.4 Regimen details APML induction therapy
More informationClinical Guidelines for Leukaemia and other Myeloid Disorders MDS
Clinical Guidelines for Leukaemia and other Myeloid Disorders MDS Reference Number Version Status Executive Lead(s) Name and Job Title Author(s) Name and Job Title 13-2H-106 2 Dr Helen Barker MDT Lead
More informationR-GDP: Rituximab, Gemcitabine, Dexamethasone &Cisplatin
: Rituximab, &Cisplatin INDICATION Relapsed or refractory Hodgkin and non-hodgkin lymphoma. Omit Rituximab for patients with Hodgkin Lymphoma. TREATMENT INTENT Palliative or curative depending on context.
More informationNCCP Chemotherapy Regimen. Tretinoin (ATRA)/Idarubicin (PETHEMA AIDA) Induction Therapy
Tretinoin INDICATIONS FOR USE: Regimen Code 00366a *Reimbursement Indicator INDICATION ICD10 Treatment of patients with newly diagnosed Acute C92 Promyelocytic Leukaemia (APL) *If a reimbursement indicator
More informationAcute myeloid leukemia: prognosis and treatment. Dimitri A. Breems, MD, PhD Internist-Hematoloog Ziekenhuis Netwerk Antwerpen Campus Stuivenberg
Acute myeloid leukemia: prognosis and treatment Dimitri A. Breems, MD, PhD Internist-Hematoloog Ziekenhuis Netwerk Antwerpen Campus Stuivenberg Patient Female, 39 years History: hypothyroidism Present:
More informationR-GDP: Rituximab, Gemcitabine, Dexamethasone &Cisplatin
: Rituximab, Gemcitabine, Dexamethasone &Cisplatin INDICATION Relapsed or refractory Hodgkin and non-hodgkin lymphoma. Omit Rituximab for patients with Hodgkin Lymphoma or high grade T cell non-hodgkin
More informationHigh Intensity Chemotherapy Guidelines for Haematology Patients at ASPH
High Intensity Chemotherapy Guidelines for Haematology Patients at ASPH Contents: Page No. 1. Overview 2 2. Admission 3 3. Admission Checklist 5 4. Inpatient management during chemotherapy 6 5. Inpatient
More informationClinical Guidelines for Leukaemia and other Myeloid Disorders MDS
Clinical Guidelines for Leukaemia and other Myeloid Disorders MDS Reference Number Version Status Executive Lead(s) Name and Job Title Author(s) Name and Job Title 13-2H-106 1 Dr Helen Barker MDT Lead
More informationStandard care plan for Carboplatin and Etoposide Chemotherapy References
CHEMOTHERAPY CARE PLAN Document Title: Document Type: Subject: Approved by: Currency: Carboplatin/Etoposide Chemotherapy Clinical Guideline Standard Care Plan 2 Years Review date: Author(s): Standard care
More informationEvolving Targeted Management of Acute Myeloid Leukemia
Evolving Targeted Management of Acute Myeloid Leukemia Jessica Altman, MD Robert H. Lurie Comprehensive Cancer Center of Northwestern University Learning Objectives Identify which mutations should be assessed
More informationLD-ARA-C and Clofarabine
LD-ARA-C and Clofarabine INDICATION Induction plus consolidation chemotherapy for patients with acute myeloid leukaemia (AML). Its use is particularly for patients over 60 years of age but it can be applied
More informationNCCP Chemotherapy Regimen. Tretinoin (ATRA)/IDArubicin (PETHEMA AIDA) Induction Therapy: High Risk
Tretinoin : High Risk INDICATIONS FOR USE: INDICATION ICD10 Regimen Code *Reimbursement Status Treatment of patients with newly diagnosed high risk Acute Promyelocytic Leukaemia (APL) C92 00366a Hospital
More informationAnand P. Jillella, MD; FACP Professor, Hematology and Medical Oncology Associate Director for Community Affairs and Outreach Winship Cancer Institute
Anand P. Jillella, MD; FACP Professor, Hematology and Medical Oncology Associate Director for Community Affairs and Outreach Winship Cancer Institute of Emory University Atlanta, GA 1 Multiple Choice #1
More informationReference: NHS England 1602
Clinical Commissioning Policy Proposition: Clofarabine for refractory or relapsed acute myeloid leukaemia (AML) as a bridge to stem cell transplantation Reference: NHS England 1602 First published: TBC
More informationMatthew Ulrickson, MD Banner MD Anderson Cancer Center September 12, 2017
Matthew Ulrickson, MD Banner MD Anderson Cancer Center September 12, 2017 Discuss the clinical presentation and diagnosis of acute leukemia * Discuss the impact of molecular features on prognosis and management
More informationTREATMENT INTENT Disease modification- see European LeukemiaNet (ELN) 2013 guidelines for treatment goals.
BOSUTINIB INDICATION Licensed / NICE TA401 (BLUETEQ required) The treatment of adult patients with chronic, accelerated and blast phase Philadelphia chromosome positive chronic myeloid leukaemia (Ph+ CML)
More informationHull and East Yorkshire and North Lincolnshire NHS Trusts Haematology Multidisciplinary Team Guideline and Pathway. Acute Myeloid Leukaemia
Hull and East Yorkshire and North Lincolnshire NHS Trusts Haematology Multidisciplinary Team Guideline and Pathway Acute Myeloid Leukaemia 1 BACKGROUND The Hull and North Lincolnshire Haematology Multidisciplinary
More informationMS.4/ 1.Nov/2015. Acute Leukemia: AML. Abdallah Abbadi
MS.4/ 1.Nov/2015. Acute Leukemia: AML Abdallah Abbadi Case 9: Acute Leukemia 29 yr old lady complains of fever and painful gums for 1 week. She developed easy bruising and hemorrhagic spots on her trunk
More informationCandidates must answer ALL questions
Time allowed: Three hours. Part 1 examination Haematology: First paper Tuesday 22 March 2016 Candidates must answer ALL questions Question 1: General Haematology A 16 year old non-european is referred
More informationNote: There are other bendamustine protocols, ensure this is the correct one for a given patient.
INDICATIONS 1 st line treatment for follicular lymphoma with FLIPI score 2 or higher: (NICE TA513- BLUETEQ required) Rituximab refractory follicular lymphoma (progression on R-chemo, R-maintenance or within
More informationRisk-adapted therapy of AML in younger adults. Sergio Amadori Tor Vergata University Hospital Rome
Risk-adapted therapy of AML in younger adults Sergio Amadori Tor Vergata University Hospital Rome Pescara 11/2010 AML: treatment outcome Age CR % ED % DFS % OS %
More informationAcute myeloid leukemia. M. Kaźmierczak 2016
Acute myeloid leukemia M. Kaźmierczak 2016 Acute myeloid leukemia Malignant clonal disorder of immature hematopoietic cells characterized by clonal proliferation of abnormal blast cells and impaired production
More informationBelgium recommendations for the management of acute promyelocytic leukaemia
6 Belgium recommendations for the management of acute promyelocytic leukaemia S. Wittnebel, MD, PhD 1 The management of acute promyelocytic leukaemia has evolved considerably. The standard front-line approach
More informationAcute Promyelocytic Leukemia: Current Management with Emphasis on Prevention of Induction Mortality
Acute Promyelocytic Leukemia: Current Management with Emphasis on Prevention of Induction Mortality Anand P. Jillella, MD, FACP Professor, Hematology and Medical Oncology Associate Director for Community
More informationThis is a controlled document and therefore must not be changed
AZACITIDINE NICE TA218 Treatment of adults not eligible for haematopoietic stem cell transplantation who have: Intermediate-2 and high-risk MDS according to the International Prognostic Scoring System
More informationMS.4/ Acute Leukemia: AML. Abdallah Al Abbadi.MD.FRCP.FRCPath Feras Fararjeh MD
MS.4/ 27.02.2019 Acute Leukemia: AML Abdallah Al Abbadi.MD.FRCP.FRCPath Feras Fararjeh MD Case 9: Acute Leukemia 29 yr old lady complains of fever and painful gums for 1 week. She developed easy bruising
More informationAML Emerging Treatment Strategies
Welcome and Introduction Clare Karten, MS Senior Director, Mission Education The Leukemia & Lymphoma Society AML Emerging Treatment Strategies Wendy Stock, MD Professor of Medicine, Section of Hematology/Oncology
More informationSOUTH THAMES CHILDREN S CANCER NETWORK GROUP. REFERRAL PROTOCOLS AND DIAGNOSIS AND STAGING PROTOCOLS October 2014
SOUTH THAMES CHILDREN S CANCER NETWORK GROUP REFERRAL PROTOCOLS AND DIAGNOSIS AND STAGING PROTOCOLS October 2014 Contents 1. Leukaemia Referral, Diagnostic and Staging Guidelines 2. Lymphoma Referral,
More informationLeukemias. Prof. Mutti Ullah Khan Head of Department Medical Unit-II Holy Family Hospital Rawalpindi Medical College
Leukemias Prof. Mutti Ullah Khan Head of Department Medical Unit-II Holy Family Hospital Rawalpindi Medical College Introduction Leukaemias are malignant disorders of the haematopoietic stem cell compartment,
More informationGroup of malignant disorders of the hematopoietic tissues characteristically associated with increased numbers of white cells in the bone marrow and
Group of malignant disorders of the hematopoietic tissues characteristically associated with increased numbers of white cells in the bone marrow and / or peripheral blood Classified based on cell type
More informationThis is a controlled document and therefore must not be changed or photocopied L.80 - R-CHOP-21 / CHOP-21
R- / INDICATION Lymphoma Histiocytosis Omit rituximab if CD20-negative. TREATMENT INTENT Disease modification or curative depending on clinical circumstances PRE-ASSESSMENT 1. Ensure histology is confirmed
More informationN Engl J Med Volume 373(12): September 17, 2015
Review Article Acute Myeloid Leukemia Hartmut Döhner, M.D., Daniel J. Weisdorf, M.D., and Clara D. Bloomfield, M.D. N Engl J Med Volume 373(12):1136-1152 September 17, 2015 Acute Myeloid Leukemia Most
More informationNCCP Chemotherapy Regimen
INDICATIONS FOR USE: Azacitidine i INDICATION ICD10 Regimen Code *Reimbursement Status Intermediate-1 and low risk myelodysplastic syndromes (MDS) according to the International Prognostic Scoring System
More informationAppendix 6: Indications for adult allogeneic bone marrow transplant in New Zealand
Appendix 6: Indications for adult allogeneic bone marrow transplant in New Zealand This list provides indications for the majority of adult BMTs that are performed in New Zealand. A small number of BMTs
More informationThe drug cost of lenalidomide for people who remain on treatment for more than 26 cycles will be met by the company.
LENALIDOMIDE MDS NICE TA322 Treatment of patients with transfusion-dependent anaemia (< 8 consecutive weeks without RBC transfusions within 16 weeks prior to commencing treatment) due to low- or intermediate-1-risk
More informationAdult Acute leukemia. Matthew Seftel. August
Adult Acute leukemia Matthew Seftel August 21 2007 mseftel@cancercare.mb.ca Principles 3 cases Diagnosis and classification of acute leukemia (AL) Therapy Emergencies Remission induction BMT Complications
More informationALL Phase 1 Induction (25-60 years)
ALL Phase 1 (25-60 years) INDICATION of remission in Adult Acute Lymphoblastic Leukaemia (ALL) patients This protocol is suitable for patients aged 25-60 years. It may sometimes be used in older patients
More informationELIGIBILITY: Newly diagnosed acute promyelocytic leukemia (APL) with low to intermediate risk (WBC less than 10 x 10 9 /L)
BCCA Protocol Summary for First-Line Induction and Consolidation Therapy of Acute Promyelocytic Leukemia Using Arsenic Trioxide and Tretinoin (All-Trans Retinoic Acid) Protocol Code Tumour Group Contact
More informationALL Phase 2 Induction (25-60 years)
ALL Phase 2 (25-60 years) INDICATION of remission in Adult Acute Lymphoblastic Leukaemia (ALL) patients This protocol is suitable for patients aged 25-60 years. It may sometimes be used in older patients
More informationELIGIBILITY: Newly diagnosed acute promyelocytic leukemia (APL) with high risk (WBC more than 10 x 10 9 /L)
BC Cancer Protocol Summary for First-Line Induction and Consolidation Therapy of Acute Promyelocytic Leukemia Using Arsenic Trioxide, Tretinoin (All-Trans Retinoic Acid) and DAUNOrubicin Protocol Code
More information5/21/2018. Disclosures. Objectives. Normal blood cells production. Bone marrow failure syndromes. Story of DNA
AML: Understanding your diagnosis and current and emerging treatments Nothing to disclose. Disclosures Mohammad Abu Zaid, MD Assistant Professor of Medicine Indiana University School of Medicine Indiana
More informationDA-EPOCH-R (Etoposide/Inpatient)
DA- (Etoposide/Inp) INDICATION High grade lymphoma. Omit rituximab if CD20 negative. PRE-ASSESSMENT 1. Ensure histology is confirmed prior to administration of chemotherapy and document in notes. 2. Record
More information3. The Clinical Management Protocols Leukaemia s (09-7A-115)
3. The Clinical Management Protocols Leukaemia s (09-7A-115) These guidelines are for use within the SY&H CCN for treatment of haematological malignancies (excluding lymphoma) in children and young persons
More informationBC Cancer Protocol Summary for Therapy of Acute Myeloid Leukemia Using azacitidine and SORAfenib
BC Cancer Protocol Summary for Therapy of Acute Myeloid Leukemia Using azacitidine and SORAfenib Protocol Code Tumour Group Contact Physician ULKAMLAS Leukemia/BMT Dr. Donna Hogge ELIGIBILITY: Acute myeloid
More informationSystemic Treatment of Acute Myeloid Leukemia (AML)
Guideline 12-9 REQUIRES UPDATING A Quality Initiative of the Program in Evidence-Based Care (PEBC), Cancer Care Ontario (CCO) Systemic Treatment of Acute Myeloid Leukemia (AML) Members of the Acute Leukemia
More informationCarfilzomib and Dexamethasone (CarDex)
Carfilzomib and Dexamethasone (CarDex) Indication Relapsed multiple myeloma for patients who have had only one previous line of therapy (that did not include bortezomib). (NICE TA457) ICD-10 codes Codes
More informationLancashire and South Cumbria Haematology NSSG Guidelines for Follicular Lymphoma:
1 Lancashire and South Cumbria Haematology NSSG Guidelines for Follicular Lymphoma: 2018-19 1.1 Pretreatment evaluation The following tests should be performed: FBC, U&Es, creat, LFTs, calcium, LDH, Igs/serum
More informationThrombohemorrhagic disorders in APL: the unsolved issue
Thrombohemorrhagic disorders in APL: the unsolved issue Pau Montesinos Hospital La Fe. Valencia, Spain 7th International Symposium on Acute Promyelocytic Leukemia Rome, Italy (September 2017) Background
More informationJordi Esteve Hospital Clínic (Barcelona) Acute Leukemia Working Party. The European Group for Blood and Marrow Transplantation
36th EBMT & 9th Data Management Group Annual Meeting Vienna, 23 March 2010 Jordi Esteve Hospital Clínic (Barcelona) Acute Leukemia Working Party The European Group for Blood and Marrow Transplantation
More informationNCCP Chemotherapy Regimen. Olaparib Monotherapy
Olaparib INDICATIONS FOR USE: INDICATION ICD10 Regimen Code *Reimbursement Indicator Maintenance treatment of adult patients with platinum -sensitive relapsed BRCAmutated (germline and/or somatic) - high
More informationGuideline for the Management of Patients with Chronic Myeloid Leukaemia (CML)
Guideline for the Management of Patients with Chronic Myeloid Leukaemia (CML) Version History Version Summary of change Date Issued 3.0 Approved by Doug Wulff on behalf of the Governance 14.11.08 Committee
More informationAcute Myeloid Leukemia
Acute Myeloid Leukemia Pimjai Niparuck Division of Hematology, Department of Medicine Ramathibodi Hospital, Mahidol University Outline Molecular biology Chemotherapy and Hypomethylating agent Novel Therapy
More informationMYELODYSPLASTIC SYNDROMES: A diagnosis often missed
MYELODYSPLASTIC SYNDROMES: A diagnosis often missed D R. EMMA W YPKEMA C O N S U LTA N T H A E M AT O L O G I S T L A N C E T L A B O R AT O R I E S THE MYELODYSPLASTIC SYNDROMES DEFINITION The Myelodysplastic
More informationAzacitidine for Treatment of Myelodysplastic Syndrome (MDS)
Azacitidine for Treatment of Myelodysplastic Syndrome (MDS) Cumbria, Northumberland, Tyne & Wear Area Team DRUG ADMINISTRATION SCHEDULE Day Drug Dose Route Site Notes 1 to 5 Azacitidine 75 mg/m 2 subcutaneous
More informationObjectives. I do not have anything to disclose.
Treatment of APL Objectives I do not have anything to disclose. Objectives 1. Urgency of early recognition and treatment 2. Treatment based on risk stratification 3. Monitoring for relapse 4. Treatment
More informationR-GemOx. Lymphoma group INDICATION. Relapsed or Refractory Lymphoma, for patients unsuitable for R-GDP regimen. Omit rituximab if CD20- negative
R-GemOx INDICATION Relapsed or Refractory Lymphoma, for patients unsuitable for R-GDP regimen. Omit rituximab if CD20- negative TREATMENT INTENT Disease modification PRE-ASSESSMENT 1. Ensure histology
More informationFLAG-Ida + Gemtuzumab Ozogamicin Regimen (Also known as FLAG-Ida + GO3x2) (AML19 Trial Course 1)
FLAG-Ida + Gemtuzumab Ozogamicin Regimen (Also known as FLAG-Ida + GO3x2) (AML19 Trial Course 1) AML19 Adults with Acute Myeloid Leukaemia or High-Risk Myelodysplastic Syndrome ***Refer to trial protocol
More informationClinical Guidelines for Lymphoid Diseases Acute Lymphoblastic Leukaemia (ALL)
Clinical Guidelines for Lymphoid Diseases Acute Lymphoblastic Leukaemia (ALL) Reference Number Version Status Executive Lead(s) Name and Job Title Author(s) Name and Job Title 13-2H-107 8 Dr Helen Barker
More informationMUD SCT for Paediatric AML?
7 th South African Symposium on Haematopoietic Stem Cell Transplantation MUD SCT for Paediatric AML? Alan Davidson Haematology / Oncology Service Red Cross Children s Hospital THE SCENARIO A 10 year old
More information4.05 Protocol name: Alemtuzumab (MabCampath ), intravenous
4.05 Protocol name: (MabCampath ), intravenous Indication Treatment of CLL refractory to fludarabine (either primary i.e. 17p deletion, or secondary i.e. following previous fludarabine treatment), without
More informationHEMATOLOGIC MALIGNANCIES BIOLOGY
HEMATOLOGIC MALIGNANCIES BIOLOGY Failure of terminal differentiation Failure of differentiated cells to undergo apoptosis Failure to control growth Neoplastic stem cell FAILURE OF TERMINAL DIFFERENTIATION
More informationSTATUS OF EARLY MORTALITY IN NEWLY DIAGNOSED CASES OF ACUTE PROMYELOCYTIC LEUKAEMIA (APL) IN BSMMU HOSPITAL
STATUS OF EARLY MORTALITY IN NEWLY DIAGNOSED CASES OF ACUTE PROMYELOCYTIC LEUKAEMIA (APL) IN BSMMU HOSPITAL RAHMAN F 1, YUNUS ABM 2, KABIR AL 3, BEGUM M 4, AZIZ A 3, SHAH S 3, RAHMAN F 5, RAHMAN MJ 6 Abstract:
More informationin people with intermediate 2 or high-risk disease, AND if the company provides ruxolitinib with the discount agreed in the patient access scheme.
RUXOLITINIB INDICATION Licensed / NICE TA386 is recommended as an option f treating disease-related splenomegaly symptoms in adults with primary myelofibrosis (also known as chronic idiopathic myelofibrosis),
More informationIndication for unrelated allo-sct in 1st CR AML
Indication for unrelated allo-sct in 1st CR AML It is time to say! Decision of allo-sct: factors to be considered Cytogenetic risk status Molecular genetics FLT3; NPM1, CEBPA. Response to induction Refractoriness
More informationCorporate Medical Policy
Corporate Medical Policy Hematopoietic Stem-Cell Transplantation for Acute Myeloid File Name: Origination: Last CAP Review: Next CAP Review: Last Review: hematopoietic_stem-cell_transplant_for_acute_myeloid_leukemia
More informationAcute leukemia. Ibrahim Aldoss, MD Assistant Professor, City of Hope Hematology and Hematopoietic Cell Transplantation
Acute leukemia Ibrahim Aldoss, MD Assistant Professor, City of Hope Hematology and Hematopoietic Cell Transplantation Helocyte- Advisory board Acute myeloid leukemia (AML) Heterogeneous clonal malignancy
More informationMANAGEMENT OF ACUTE LYMPHOBLASTIC LEUKEMIA. BY Dr SUBHASHINI 1 st yr PG DEPARTMENT OF PEDIATRICS
MANAGEMENT OF ACUTE LYMPHOBLASTIC LEUKEMIA BY Dr SUBHASHINI 1 st yr PG DEPARTMENT OF PEDIATRICS Introduction The management of ALL, the most common childhood malignancy (1/3 rd of all malignancy), has
More informationAcute Leukaemia Quality Performance Indicators
Acute Leukaemia Quality Performance Indicators Patients diagnosed between July 2014 and June 2017 Publication date 19 June 2018 An Official Statistics publication for Scotland This is an Official Statistics
More informationChronic Myeloid Leukaemia Guidelines
Chronic Myeloid Leukaemia Guidelines Approved by Pathway Board for Haematological Malignancies Coordinating author: Heather Oakervee, Bart s Health NHST Date of issue: 12.03.2015 Version number:v1.0 These
More informationBlood Cancers in the Community
Over to you, mate Blood Cancers in the Community National Rural Health Conference NZ Rural General Practice Network April 7, 2018 Brian Grainger Haematology Registrar Auckland Acknowledgements Dr James
More informationWelcome and Introductions
Information for Patients With Acute Myeloid Leukemia (AML) Welcome and Introductions Information for Patients With Acute Myeloid Leukemia (AML) Mark B. Juckett, MD Vice Chair for Clinical Affairs and Quality
More informationCD20-positive high-grade non-hodgkin Lymphoma in patients in which R-CHOP is not indicated
INDICATION CD20-positive high-grade non-hodgkin Lymphoma in patients in which R-CHOP is not indicated TREATMENT INTENT Curative or Disease Modification. PRE-ASSESSMENT 1. Ensure histology is confirmed
More informationHull and East Yorkshire and North Lincolnshire NHS Trusts Haematology Multidisciplinary Team Guideline and Pathway. Chronic Myeloid Leukaemia
Hull and East Yorkshire and North Lincolnshire NHS Trusts Haematology Multidisciplinary Team Guideline and Pathway Chronic Myeloid Leukaemia 1 BACKGROUND The Hull and North Lincolnshire Haematology Multidisciplinary
More informationAcute Leukemia. Maureen Carr, MN, RN, AGPCNP-BC, AOCNP Hematology and Hematopoietic Cell Transplantation
Acute Leukemia Maureen Carr, MN, RN, AGPCNP-BC, AOCNP Hematology and Hematopoietic Cell Transplantation Disclosures Jazz Pharmaceuticals Speaker Bureau Acute myeloid leukemia (AML) Heterogeneous clonal
More informationStem cell transplantation for patients with AML in Republic of Macedonia: - 15 years of experience -
Stem cell transplantation for patients with AML in Republic of Macedonia: - 15 years of experience - R E S E A R C H A S S O C I A T E P R O F. D - R Z L A T E S T O J A N O S K I Definition Acute myeloid
More informationPOMALIDOMIDE AND LOW DOSE DEXAMETHASONE
POMALIDOMIDE AND LOW DOSE DEXAMETHASONE INDICATION Multiple myeloma at third or subsequent relapse, i.e. after 3 previous treatments including both lenalidomide and bortezomib. (NICE TA427 -BLUETEQ required)
More informationR-FC for Chronic Lymphocytic Leukaemia LKWOS-005/01
West of Scotland Cancer Network Chemotherapy Protocol R-FC for Chronic Lymphocytic Leukaemia LKWOS-005/01 Indication B cell Chronic Lymphocytic Leukaemia First line therapy in patients under 70 years of
More informationTumour Lysis Syndrome (TLS)
(TLS) Overview: Tumour lysis syndrome refers to a number of metabolic disturbances (hyperuricaemia, hyperphosphataemia, hyperkalaemia and hypocalcaemia) that occur as the result of rapid cell lysis. This
More informationStandard care plan for 1 st line palliative chemotherapy in advanced non small cell lung cancer References
CHEMOTHERAPY CARE PLAN Document Title: Document Type: Subject: Approved by: Currency: Carboplatin & Gemcitabine combination chemotherapy (Lung cancer) Clinical Guideline Standard Care Plan 2 Years Review
More information(primary CNS lymphoma)
(primary CNS lymphoma) INDICATION CNS Lymphoma TREATMENT INTENT Curative PRE-ASSESSMENT 1. Ensure histology is confirmed and documented in the notes. Although it is sometimes difficult to obtain tissue
More information2.07 Protocol Name: CHOP & Rituximab
2.07 Protocol Name: CHOP & Rituximab Indication Intermediate and high grade, B-cell non-hodgkins lymphoma expressing CD20. Second or third line therapy for low grade, B cell non- Hodgkins lymphoma expressing
More informationCARFILZOMIB/ LENALIDOMIDE / DEXAMETHASONE (Car/Len/Dex)
CARFILZOMIB/ LENALIDOMIDE / DEXAMETHASONE (Car/Len/Dex) INDICATIONS Relapsed multiple myeloma This combination is not funded by NHS England. Individual funding must be agreed prior to initiation. TREATMENT
More informationSkin Pathway Group Alemtuzumab in Cutaneous Lymphoma
Skin Pathway Group Alemtuzumab in Cutaneous Lymphoma Indication: Treatment of patients with Cutaneous Lymphoma (Unlicensed use) Disease control prior to Reduced Intensity Conditioning Stem Cell Transplant
More informationSWOG ONCOLOGY RESEARCH PROFESSIONAL (ORP) MANUAL LEUKEMIA FORMS CHAPTER 16A REVISED: DECEMBER 2017
LEUKEMIA FORMS The guidelines and figures below are specific to Leukemia studies. The information in this manual does NOT represent a complete set of required forms for any leukemia study. Please refer
More informationAcute Myeloid Leukemia: A Patient s Perspective
Acute Myeloid Leukemia: A Patient s Perspective Patrick A Hagen, MD, MPH Cardinal Bernardin Cancer Center Loyola University Medical Center Maywood, IL Overview 1. What is AML? 2. Who gets AML? Epidemiology
More informationBortezomib, Thalidomide and Dexamethasone (VTD) 28 day
Bortezomib, Thalidomide and Dexamethasone (VTD) 28 day Indication First line treatment of multiple myeloma in patients who are eligible for stem cell transplantation. (NICE TA311) ICD-10 codes Codes with
More informationAML in elderly. D.Selleslag AZ Sint-Jan Brugge, Belgium 14 December 2013
AML in elderly D.Selleslag AZ Sint-Jan Brugge, Belgium 14 December 2013 AML is predominantly a disease of the elderly incidence 2 3/100.000 SEER Cancer Statistics, National Cancer Institute, USA 2002 2006
More informationClinical & Laboratory Assessment
Clinical & Laboratory Assessment Dr Roger Pool NHLS & University of Pretoria Clinical Assessment (History) Anaemia ( haemoglobin) Dyspnoea (shortness of breath) Tiredness Angina Headache Clinical Assessment
More informationSPECIAL AUTHORIZATION REQUEST FOR COVERAGE OF HIGH COST CANCER DRUGS
SPECIAL AUTHORIZATION REQUEST FOR COVERAGE OF HIGH COST CANCER DRUGS (Filgrastim, Capecitabine, Imatinib, Dasatinib, Erolotinib, Sunitinib, Pazopanib, Fludarabine, Sorafenib, Crizotinib, Tretinoin, Nilotinib,
More informationAcute Promyelocytic Leukemia
Acute Promyelocytic Leukemia Outline of Management Suleimman AlSweedan,MD,MS,FAAP Consultant Pediatric Hematology/oncology TABLE OF CONTENTS Background 3 Pediatric APL Trials 4 Adult APL Trials 4 Diagnostic
More informationDr Kavita Raj Consultant Haematologist Guys and St Thomas Hospital
Dr Kavita Raj Consultant Haematologist Guys and St Thomas Hospital IPSS scoring system Blood counts Bone marrow blast percentage Cytogenetics Age as a modulator of median survival IPSS Group Median Survival
More informationAcute Lymphoblastic Leukemia (ALL) Ryan Mattison, MD University of Wisconsin March 2, 2010
Acute Lymphoblastic Leukemia (ALL) Ryan Mattison, MD University of Wisconsin March 2, 2010 ALL Epidemiology 20% of new acute leukemia cases in adults 5200 new cases in 2007 Most are de novo Therapy-related
More informationCLINICAL STUDY REPORT SYNOPSIS
CLINICAL STUDY REPORT SYNOPSIS Document No.: EDMS-PSDB-5412862:2.0 Research & Development, L.L.C. Protocol No.: R115777-AML-301 Title of Study: A Randomized Study of Tipifarnib Versus Best Supportive Care
More informationAIH, Marseille 30/09/06
ALLOGENEIC STEM CELL TRANSPLANTATION FOR MYELOID MALIGNANCIES Transplant and Cellular Therapy Unit Institut Paoli Calmettes Inserm U599 Université de la Méditerranée ée Marseille, France AIH, Marseille
More informationALL CONSOLIDATION- Cycle 3 (25-60 years)
ALL CONSOLIDATION- (25-60 years) INDICATION Adult Acute Lymphoblastic Leukaemia (ALL) in remission not eligible for allogeneic transplantation This protocol is suitable for patients aged 25-60 years. It
More informationCARFILZOMIB /DEXAMETHASONE (CarDex)
CARFILZOMIB /DEXAMETHASONE (CarDex) INDICATIONS First Relapse multiple myeloma in bortezomib naïve patients [NICE TA457] Requires Blueteq Application TREATMENT INTENT Disease modification PRE-ASSESSMENT
More informationCorporate Medical Policy. Policy Effective February 23, 2018
Corporate Medical Policy Genetic Testing for FLT3, NPM1 and CEBPA Mutations in Acute File Name: Origination: Last CAP Review: Next CAP Review: Last Review: genetic_testing_for_flt3_npm1_and_cebpa_mutations_in_acute_myeloid_leukemia
More informationAllogeneic Hematopoietic Stem-Cell Transplantation for Myelodysplastic Syndromes and Myeloproliferative Neoplasms. Policy Specific Section:
Medical Policy Allogeneic Hematopoietic Stem-Cell Transplantation for Myelodysplastic Syndromes and Myeloproliferative Type: Medical Necessity and Investigational / Experimental Policy Specific Section:
More information